1. Introduction {#sec1-materials-12-01015}
===============

Within the field of biomedical therapeutics, we can highlight the concept of tissue engineering to refer to the development of procedures and biomaterials that aim to devise new tissues to replace those damaged, following the principles of cellular and molecular biology and taking as a premise the search for "biological solutions for biological problems" \[[@B1-materials-12-01015]\].

In 2007, the American Association of Endodontists adopted the term "regenerative endodontics" to refer to the concept of tissue engineering applied to the restoration of root canal health, in a way that continuous development of the root and tissues surrounding it is promoted \[[@B2-materials-12-01015]\].

The introduction of the so-called bioceramic materials meant a great advance for this new paradigm in endodontic therapy \[[@B3-materials-12-01015]\], given their biocompatible nature and excellent physicochemical properties \[[@B4-materials-12-01015]\]. Categorized as bioinert, bioactive and biodegradable \[[@B5-materials-12-01015]\], dentistry-applied bioceramic materials are ceramic materials which share a common characteristic of being specifically designed to fulfil their function; they are able to act as root canal sealers, cements, root repair or filling materials \[[@B4-materials-12-01015]\]. Applied to vital pulp therapy, bioceramic materials can be used in cases of pulp exposition from trauma, caries or other mechanical causes, as direct pulp cappers \[[@B6-materials-12-01015]\].

Properties like biocompatibility and bioactivity are to be expected in dentistry-applied bioceramic materials for their use in vital pulp therapy \[[@B7-materials-12-01015]\]. The first one refers to the "ability to perform as a substrate that will support the appropriate cellular activity, including the facilitation of molecular and mechanical signaling systems, in order to optimize tissue regeneration, without eliciting any undesirable local or systemic responses in the eventual host" \[[@B8-materials-12-01015]\], while bioactivity goes even further, and is only attributed to those materials which are capable of inducing a desired tissue response from the host \[[@B9-materials-12-01015]\] by the use of biomimetic approaches \[[@B10-materials-12-01015]\]. The term differs depending on the field in which it is implemented, being related to the cellular effects induced by biologically active ions and substances released from biomaterials in the field of tissue engineering, but referred to as the biomaterial's capability of forming hydroxyl apatite mineral on its surface both in vitro and in vivo in the field of biomaterial science \[[@B11-materials-12-01015]\].

Considering these desirable characteristics of bioceramic materials, it seems convenient to analyze the interaction between human dental pulp stem cells (hDPSCs), which are post-natal stem cells with mesenchymal stem cell (MSCs)-like characteristics, like auto-renewal ability and multilineage differentiation potential \[[@B12-materials-12-01015]\], and them; as their combined use could mean and advancement in the field of regenerative endodontics.

Cytotoxicity and biocompatibility of a wide range of bioceramic materials towards dental stem cells (DSCs) have been investigated in numerous studies \[[@B13-materials-12-01015],[@B14-materials-12-01015],[@B15-materials-12-01015],[@B16-materials-12-01015],[@B17-materials-12-01015]\]; among others. The well-known Pro-Root MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) has been shown to increase osteoblast, fibroblast, cementoblast, odontoblast and pulp cell differentiation, but its handling difficulty among other limitations encourages for a search for alternative materials \[[@B13-materials-12-01015]\]. Materials like Biodentine (Septodont, Saint Maurdes-Fosses, France) and TheraCal LC (Bisco Inc., Schaumburg, IL, USA) are examples of bioceramic materials introduced posteriorly in dentistry for their use in vital pulp therapy as blood clot protectors in pulpal revascularization procedures, standing out for their consistency, easier manipulation and tricalcium silicate composition \[[@B16-materials-12-01015]\].

However, to the best of the authors' knowledge, there has been no effort to sort and summarize studies analyzing bioactivity of such materials into more homogenous subgroups that would allow for an easier analysis of the evidence.

The aim of this study is to present a systematic review of available literature investigating bioactivity of dentistry-applied bioceramic materials towards dental pulp stem cells; including a bibliometric analysis of such group of studies and a presentation of the parameters used to assess bioactivity, materials studied and summary of results.

2. Materials and Methods {#sec2-materials-12-01015}
========================

This systematic review was conducted in accordance with the PRISMA guidelines or preferred reporting items for systematic reviews and meta-analyses \[[@B18-materials-12-01015]\]. Our review was not eligible for registration with PROSPERO, as it did not involve health studies in which participants were people nor animal research studies exclusively.

In terms of the research question, based on the PICO model, our review aimed to assess the current knowledge on dentistry-based bioceramic materials by exploring to what extent they express bioactive properties in in vitro assays and animal studies when exposed to dental pulp stem cells, as opposed to a control or compared to different bioceramic material compositions, for their use in the dentin-pulp complex therapy.

2.1. Inclusion and Exclusion Criteria {#sec2dot1-materials-12-01015}
-------------------------------------

Studies assessing bioactivity of one or more bioceramic materials (both commercially available or novel/experimental) towards DPSCs were included in our review. We established bioactivity assessment as any test or measurement for odontogenic, osteogenic, angiogenic and/or mineralization potential of DPSCs exposed both directly or indirectly to bioceramic materials. Studies assessing cytotoxicity and/or biocompatibility alone i.e., cell viability or proliferation were excluded. Studies assessing any other type of stem cell apart from DPSCs were also excluded.

The series of inclusion and exclusion criteria were established by a consensus reached from all authors after discussion, considering the research question and the objectives of the study while aiming for an ample range of results to be provided from the search.

2.2. Search Strategy {#sec2dot2-materials-12-01015}
--------------------

### 2.2.1. Sources of Information {#sec2dot2dot1-materials-12-01015}

To identify potentially relevant studies, a thorough electronic search was made in PubMed, Web of Science, Scopus, Embase, Cochrane, and Lilacs databases. Study search was performed during October, November and December 2018. In particular cases, the authors of the articles were contacted by email to request missing information. The structured search strategy and data extraction were conducted by an individual examiner.

### 2.2.2. Search Terms {#sec2dot2dot2-materials-12-01015}

The search strategy included 6 Mesh (Medical Subject Heading) terms: "Silicate", "Calcium Silicate", "Calcium phosphate", "Calcium aluminosilicate", "Hydroxyapatite" and "Gene Expression"; and 13 uncontrolled descriptors: "Bioceramic", "Bioceramics", "Bioactivity", "Bioactive", "Mineralisation", "Mineralization", "Differentiation", "Proliferation", "Odontogenic", "Osteogenic", "Dentinogenic", "Cementogenic" and "Dental Stem Cells". Boolean operators ("OR" and "AND") were used to join search terms related to the search question ([Figure 1](#materials-12-01015-f001){ref-type="fig"}).

### 2.2.3. Study Selection {#sec2dot2dot3-materials-12-01015}

Articles identified using the search terms were exported to RefWorks (ProQuest, MI, USA) to check for duplicates. Once duplicates were discarded, a first screening of record titles and abstracts was carried out according to the previously described inclusion and exclusion criteria. Remaining studies were assessed for eligibility and qualitative synthesis by full-text screening.

### 2.2.4. Study Data {#sec2dot2dot4-materials-12-01015}

For the bibliometric analysis, the following variables were recorded for each article: author and year of publication, journal, country, and institution. For the synthesis of study methodology, a summary of the materials and methods of included studies was transcribed by listing the following variables: study type, bioceramic materials used, bioactivity analysis and duration of the analysis. For the synthesis of results, studies were categorized in terms of the significant results found, the duration in which these significant results were found, and their significance level.

2.3. Quality Assessment {#sec2dot3-materials-12-01015}
-----------------------

The quality of the studies was assessed using a modified CONSORT checklist of items for reporting in vitro studies of dental materials \[[@B19-materials-12-01015]\] and the ARRIVE guidelines for reporting animal research \[[@B20-materials-12-01015]\].

3. Results {#sec3-materials-12-01015}
==========

3.1. Study Selection and Flow Diagram {#sec3dot1-materials-12-01015}
-------------------------------------

The search identified 1023 preliminary references related to the bioactivity of bioceramic materials towards dental stem cells, of which 355 were found in PubMed, 473 in Web of Science, 179 in Embase, 15 in Scopus, and 1 in Cochrane databases. Search made in LILACS produced no results. After excluding 203 duplicates, the remaining 820 were screened. Of these, 783 were excluded on reading the title and abstract as they did not fulfil our inclusion criteria. The resulting 37 articles were examined at full-text level, and all of them resulted to be eligible for our review ([Figure 2](#materials-12-01015-f002){ref-type="fig"}).

3.2. Study Characteristics {#sec3dot2-materials-12-01015}
--------------------------

### 3.2.1. Bibliometric Analysis {#sec3dot2dot1-materials-12-01015}

All corresponding authors of the included studies were associated with an academic institution or university. The distribution of included studies by year of publication, country, and journal is presented in [Figure 3](#materials-12-01015-f003){ref-type="fig"}.

### 3.2.2. Bioactivity Analysis {#sec3dot2dot2-materials-12-01015}

A wide range of analyses of bioactivity were presented from the included studies. The most common analysis was the quantification of the expression of odontogenic, osteogenic and/or angiogenic markers or genes using reverse transcription polymerase reaction (RT-PCR), followed by alkaline phosphatase (ALP) enzyme activity assays and Alizarin Red Staining (ARS) to assess mineralization potential.

Other analyses include western blot, micro-computed tomography (micro-CT), scanning electron microscopy (SEM), attenuated total reflectance-Fourier transform infrared (ATR-FTIR), transmission electron microscopy (TEM), histological analysis, immuno-fluorescence, and immuno-histochemical assays. Bioactivity analyses alongside with their duration and a description of the study associated with them are presented in [Table 1](#materials-12-01015-t001){ref-type="table"}.

### 3.2.3. Study Type {#sec3dot2dot3-materials-12-01015}

Articles included fell into two main categories in terms of type of study: in vitro, or animal study. In some cases, articles presented both an in vitro and an animal study \[[@B26-materials-12-01015],[@B27-materials-12-01015],[@B37-materials-12-01015]\]. There were two studies which analyzed bioactivity of bioceramic materials towards hDPSCs ex vivo \[[@B33-materials-12-01015],[@B42-materials-12-01015]\].

### 3.2.4. Cell Variant {#sec3dot2dot4-materials-12-01015}

All studies included used dental pulp stem cells (DPSCs) as their cell variant to assess bioceramic material bioactivity.

### 3.2.5. Bioceramic Materials Used {#sec3dot2dot5-materials-12-01015}

Bioceramic materials studied ranged from commercially available ([Table 2](#materials-12-01015-t002){ref-type="table"}) to novel or experimental materials ([Table 3](#materials-12-01015-t003){ref-type="table"}). A separate category was presented for bioceramic materials which were combined with an additive for their analysis ([Table 4](#materials-12-01015-t004){ref-type="table"}).

3.3. Quality Assessment {#sec3dot3-materials-12-01015}
-----------------------

All in vitro studies analyzed using the modified CONSORT checklist \[[@B19-materials-12-01015]\] ([Table 5](#materials-12-01015-t005){ref-type="table"}) presented a structured abstract (item 1) and an introduction which provided information about the background of the bioceramic material and/or bioactivity analysis studied (item 2a). Within the introduction, the majority of studies presented clear objectives and hypotheses (item 2b). Description of methodology as well as of the variables studied was sufficiently clear to allow for replication in all studies (items 3 and 4), but none of them presented a detailed report of the calculation of sample size or random allocation sequence (items 5--9). All studies indicated the statistical method used (item 10), but presented significance level as *p* values, and not confidence intervals (item 11). Discussions generally included a brief synopsis of the key findings and comparisons with relevant findings from other published studies, but often failed to address the limitations of the studies, which we considered as a reason for non-fulfillment (item 12). Sources of funding (if any) were indicated in the majority of studies (item 13), and indications for access to full trial protocols were obviated in all studies (item 14).

Only three out of the five animal studies analyzed using the ARRIVE guidelines \[[@B20-materials-12-01015]\] ([Table 6](#materials-12-01015-t006){ref-type="table"}) were headed with a sufficiently descriptive title (item 1), but all of them provided a detailed abstract (item 2). All studies provided sufficient scientific background (item 3a) and established clear objectives (item 4) in the introduction, but failed to justify the use of the animal species studied to address the scientific objectives (item 3b). Ethical statements were clear in all studies (item 5), and study design, experimental procedures were detailed enough in all except one (items 6 and 7). Details about the experimental animals and how they were distributed in the study design were included in every study (items 8--11 and 14), but housing and husbandry information was obviated in all cases (item 9). Both experimental outcomes and statistical methods were described in all studies (items 12 and 13). All studies reported the results for each analysis carried out with a measure of precision (item 15), but all of them failed to report baseline data about health status of the animals studied and any adverse effects they could have suffered after the experiment (items 14 and 17). Lastly, items referring to the discussion were fulfilled by all studies (items 18--20).

3.4. Study Tesults {#sec3dot4-materials-12-01015}
------------------

Significant results from included in vitro studies are presented in [Table 7](#materials-12-01015-t007){ref-type="table"}, [Table 8](#materials-12-01015-t008){ref-type="table"}, [Table 9](#materials-12-01015-t009){ref-type="table"}, [Table 10](#materials-12-01015-t010){ref-type="table"}, [Table 11](#materials-12-01015-t011){ref-type="table"}, [Table 12](#materials-12-01015-t012){ref-type="table"}, [Table 13](#materials-12-01015-t013){ref-type="table"}, [Table 14](#materials-12-01015-t014){ref-type="table"}, [Table 15](#materials-12-01015-t015){ref-type="table"}, [Table 16](#materials-12-01015-t016){ref-type="table"} and [Table 17](#materials-12-01015-t017){ref-type="table"}, and significant results from included animal research studies are presented in [Table 18](#materials-12-01015-t018){ref-type="table"}.

### 3.4.1. Results for RT-PCR Analysis {#sec3dot4dot1-materials-12-01015}

Results for bioactivity-related marker expression using RT-PCR comparing a bioceramic material with mineral trioxide aggregate (Nex MTA/PR-MTA/MTA) showed positive significant results for the studied bioceramic materials (Exp. PPL and BD, \[[@B22-materials-12-01015]\]; Nano-HA, \[[@B21-materials-12-01015]\]), or mixed results depending on the gene/marker studied (Quick-Set2, \[[@B31-materials-12-01015]\]) or the concentration of material used (iRoot BP, ([@B56-materials-12-01015]\]) \[[Table 7](#materials-12-01015-t007){ref-type="table"}).

All studies comparing a bioceramic material and an additive with the bioceramic material itself showed positive significant results for the bioceramic material in combination with the additive (GNP-CPC, \[[@B25-materials-12-01015]\]; SC + LLLI, \[[@B30-materials-12-01015]\]; CPC-BGN, \[[@B32-materials-12-01015]\]; hTDM/SC, \[[@B33-materials-12-01015]\]; MTA-CaCl~2~ and MTA-Na~2~HPO~4~, \[[@B46-materials-12-01015]\]), except for one case (MTA+UW/PG, \[[@B35-materials-12-01015]\]) in which the bioceramic material itself produced better results ([Table 8](#materials-12-01015-t008){ref-type="table"}).

The majority of studies comparing a bioceramic material and a control showed positive significant results for the bioceramic material (Gel-HA-TCP, \[[@B23-materials-12-01015]\]; Zn0/1/2/3, \[[@B28-materials-12-01015]\]; Quick-set2 and PR-MTA, \[[@B31-materials-12-01015]\]; MTA and BD, \[[@B34-materials-12-01015]\]; BD, \[[@B38-materials-12-01015]\]; MTA, \[[@B40-materials-12-01015]\]; MTA, \[[@B43-materials-12-01015]\]; MTA, \[[@B44-materials-12-01015]\]; MTA and Theracal, \[[@B49-materials-12-01015]\]; MTA and BD, \[[@B50-materials-12-01015]\]; CaSi-αTCP, \[[@B51-materials-12-01015]\]; CSP, \[[@B54-materials-12-01015]\]; Ca~3~SiO~5~, \[[@B57-materials-12-01015]\]), and the rest showed mixed results depending on de gene/marker studied (Exp. PPL, BD and Nex-MTA, \[[@B22-materials-12-01015]\]; HA-CPC, \[[@B26-materials-12-01015]\]; SC, \[[@B33-materials-12-01015]\]; CaP, \[[@B41-materials-12-01015]\]; FS and BD, \[[@B48-materials-12-01015]\]) ([Table 9](#materials-12-01015-t009){ref-type="table"}).

Studies comparing a bioceramic material and a non-bioceramic material did not show positive significant results for the bioceramic materials studied. One of the studies showed that DDM produced a greater bioactivity-related gene expression than HA-CPC \[[@B26-materials-12-01015]\]; and the other one showed mixed results for Ca~3~SiO~3~, which produced a greater expression of some markers but not others compared to Ca(OH)~2~ \[[@B57-materials-12-01015]\] ([Table 10](#materials-12-01015-t010){ref-type="table"}).

### 3.4.2. Results for ARS Staining {#sec3dot4dot2-materials-12-01015}

Results for ARS staining comparing a bioceramic material with mineral trioxide aggregate (MTA, PR-MTA) showed negative significant results for the studied bioceramic materials (Quick-Set2, \[[@B31-materials-12-01015]\]; Theracal, \[[@B49-materials-12-01015]\]) ([Table 11](#materials-12-01015-t011){ref-type="table"}).

Both studies comparing a bioceramic material and an additive with the bioceramic material itself showed positive significant results for the bioceramic material in combination with the additive (γION-CPC and αION-CPC, \[[@B24-materials-12-01015]\]; GNP-CPC, \[[@B25-materials-12-01015]\]) ([Table 12](#materials-12-01015-t012){ref-type="table"}).

All studies comparing a bioceramic material and a control showed positive significant results for the bioceramic materials studied (Gel-HA-TCP, \[[@B23-materials-12-01015]\]; Zn0/1/2/3, \[[@B28-materials-12-01015]\]; PR-MTA and Quick-Set2, \[[@B31-materials-12-01015]\]; BD, Theracal and MTA, \[[@B34-materials-12-01015]\]; BD, \[[@B38-materials-12-01015]\]; MTA, \[[@B40-materials-12-01015]\]; CaP, \[[@B41-materials-12-01015]\]; FS0.2, \[[@B48-materials-12-01015]\]; PR-MTA and Theracal, \[[@B49-materials-12-01015]\]; Ca~3~SiO~5~, \[[@B57-materials-12-01015]\]) ([Table 13](#materials-12-01015-t013){ref-type="table"}).

### 3.4.3. Results for ALP Activity {#sec3dot4dot3-materials-12-01015}

There was only one study comparing a bioceramic material with MTA in terms of ALP activity, and it produced negative results for the bioceramic material studied (Quick-Set2, \[[@B31-materials-12-01015]\]). The rest of the studies compared two different biomaterials or different concentrations of the same bioceramic material ([Table 14](#materials-12-01015-t014){ref-type="table"}).

All studies comparing a bioceramic material and an additive with the bioceramic material itself showed positive significant results for the bioceramic material in combination with the additive (γION-CPC and αION-CPC, \[[@B24-materials-12-01015]\]; GNP-CPC, \[[@B25-materials-12-01015]\]; CPC-BGN, \[[@B32-materials-12-01015]\]; MTA-CaCl~2~ and MTA-NA~2~HPO~4~, \[[@B46-materials-12-01015]\]), except for one (SC \[[@B30-materials-12-01015]\]) ([Table 15](#materials-12-01015-t015){ref-type="table"}).

The majority of studies comparing a bioceramic material and a control showed positive significant results for the bioceramic materials studied (Gel-HA-TCP, \[[@B23-materials-12-01015]\]; Zn0/1/2/3, \[[@B28-materials-12-01015]\]; PR-MTA and Quick-Set2, \[[@B31-materials-12-01015]\]; SC, \[[@B33-materials-12-01015]\]; BD, Theracal and MTA, \[[@B34-materials-12-01015]\]; BD, \[[@B38-materials-12-01015]\]; CaP, \[[@B41-materials-12-01015]\]; CSC, \[[@B47-materials-12-01015]\]; FS and BD \[[@B48-materials-12-01015]\]; CSP50/100/200, \[[@B54-materials-12-01015]\]; Ca~3~SiO~5~, \[[@B57-materials-12-01015]\]). One of them showed mixed results depending on the duration of exposure (MTA, \[[@B40-materials-12-01015]\]) and the remaining two studies showed negative significant results for the bioceramic materials studied (MTA, \[[@B36-materials-12-01015]\]; MTAP and MTAF, \[[@B52-materials-12-01015]\]) ([Table 16](#materials-12-01015-t016){ref-type="table"}).

### 3.4.4. Results for Other Bioactivity-Related Analyses {#sec3dot4dot4-materials-12-01015}

Western blot analyses showed mixed results for Zn0/1/2/3 compared to a control \[[@B28-materials-12-01015]\], and a higher expression of bioactivity-related markers by PR-MTA compared to Quick-Set2, and by both of them compared to a control \[[@B31-materials-12-01015]\]. ATR-FTIR showed positive results for PR-MTA compared to Quick-Set2, and for both of them compared to a control \[[@B31-materials-12-01015]\]. ELISA showed mixed results for MTA and CEM \[[@B39-materials-12-01015]\]. Assessment of the level of grey in mineralization nodules using Gene Tool showed positive significant results for PLGA/TCP compared to PLGA/HA and PLGA/CDHA \[[@B42-materials-12-01015]\]. Lastly, both the TRACP & ALP assay kit (Takahara, Shiga, Japan) and the OC and DSP emzyme-linked immunosorbent assay kit (Thermo Fisher Scientific, Waltham, MA, USA) showed that the addition of polydopamine to PR-MTA produced better results than PR-MTA itself.

4. Discussion {#sec4-materials-12-01015}
=============

The attractiveness of bioceramic materials for their desirable properties added to their constant development, the demand for new advances and the ampliation of treatment indications results in an overflow of related literature over time. Therefore, it seems convenient to establish an updated and organized vision of the commercially available and experimental dentistry-applied bioceramic materials' characteristics. With this in mind, the aim of this study was to present a systematic review of available literature investigating bioactivity of these materials towards dental pulp stem cells.

In terms of results, it can be highlighted that the most common method used to assess bioactivity in the included studies was the expression of bioactivity-related markers using reverse transcriptase polymerase chain reaction or RT-PCR. A recent systematic review illustrates this tendency by assessing gene expression of dental pulp cells in response to tricalcium silicate cements \[[@B58-materials-12-01015]\]. Studies also tended to compare new bioceramic materials with the established mineral trioxide aggregate or the more recently introduced Biodentine, as shown in [Table 2](#materials-12-01015-t002){ref-type="table"}, in which they appear as the most studied materials.

The use of additives in combination with bioceramic materials looks promising, in some cases enhancing or positively influencing the material's results in bioactivity assays in comparison with the bioceramic material itself. For example, positive significant results have been shown for iron oxide \[[@B24-materials-12-01015]\], gold \[[@B25-materials-12-01015]\], and bioactive glass \[[@B32-materials-12-01015]\] nanoparticles in combination with calcium phosphate. However, we need to interpret these results with caution, being able to extrapolate them to clinical practice only when a clear dosage or ratio for the additive and bioceramic material has been established in controlled clinical trials.

New material compositions being studied also need to be taken into consideration for future investigations, as some of them have shown positive significant results in bioactivity assays. Novel materials like Exp. PPL \[[@B22-materials-12-01015]\], Gelatin-HA-TCP \[[@B23-materials-12-01015]\] and Zinc Bioglass (Zn0/1/2/3) \[[@B28-materials-12-01015]\] have all shown positive significant results for ARS staining and ALP activity assay compared to a control, and more specifically, Exp. PPL has shown a greater expression of DSPP and OCN compared to MTA and a control; Gelatin-HA-TCP has shown a greater expression of RUNX2, OSX and BSP compared to a control; and Zinc Bioglass (Zn0/1/2/3) has shown a greater expression of RUNX2, ON, CON, MEPE, BSP, and BMP-2 compared to a control. So again, in order to extrapolate these results to clinical practice, it would be interesting to carry out further studies investigating these biomaterials in different conditions.

When assessing quality and risk of bias, included studies referred a similar structural pattern. They reported essential data like a sufficient abstract, a clear objective or objectives, a detailed description of methodology, a mention of the statistical tests used and relevant conclusions; but often failed to justify the sample size used, to describe the randomization process used (if any), and most importantly to address the study's limitations in the discussion. It may be worth noticing for future reviews that a checklist for reporting in vitro studies or "CRIS" guideline is under development \[[@B59-materials-12-01015]\] to address the need for uniform methodology in the assessment of this type of studies.

The introduction of new bioceramic materials and the use of additives in combination with them calls for updated research in the field. At the current state, bioactivity assessment of these materials towards dental pulp stem cells centers on in vitro assays or animal research at most. For future studies, it could be interesting to explore the mechanisms with which this bioactivity is achieved and move on towards in vivo trials.

5. Conclusions {#sec5-materials-12-01015}
==============

Quantification of osteogenic, odontogenic and angiogenic markers using reverse transcriptase polymerase chain reaction or RT-PCR is the prevailing method used to evaluate bioceramic material bioactivity towards DPSCs in the current investigative state, followed by alkaline phosphatase (ALP) enzyme activity assays and Alizarin Red Staining (ARS) to assess mineralization potential. Mineral trioxide aggregate and Biodentine are the prevalent reference materials used to compare with newly introduced bioceramic materials. Available literature compares a wide range of bioceramic materials for bioactivity, consisting majorly of in vitro assays. The desirability of this property added to the rapid introduction of new material compositions makes this subject a clear candidate for future research.

J.L.S. wrote the paper; L.F., C.L., F.J.R.-L. and S.S. supervised the content.
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materials-12-01015-t001_Table 1

###### 

Summary of the methodology of included studies.

  Cell Variant                                                                  Study Type                                Bioceramics Used                          Author                                              Bioactivity Analysis \*                                                                          Duration
  ----------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------ ---------------------
  hDPSCs                                                                        In vitro                                  MTA, Nano-HA                              Hanafy et al. \[[@B21-materials-12-01015]\]         RT-PCR (Runx2, OCN, ALP, COL1α, OPN);                                                            21 days
  ARS                                                                           21 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  Exp. PPL, BD, Nex-MTA                     Pedano et al. \[[@B22-materials-12-01015]\]         RT-PCR (OCN, DSPP, ALP)                                                                          4, 10 and 14 days
  hDPSCs                                                                        In vitro                                  Gelatin-HA-TCP (10:1:1)                   Gu et al. \[[@B23-materials-12-01015]\]             RT-PCR (Runx2, OSX, BSP);                                                                        4, 7 and 14 days
  ALP activity;                                                                 4, 7 and 14 days                                                                                                                                                                                                                         
  ARS                                                                           14 and 21 days                                                                                                                                                                                                                           
  hDPSCs                                                                        In vitro                                  aIONP-CPC, bIONP-CPC                      Xia et al. \[[@B24-materials-12-01015]\]            RT-PCR (ALP, COL1α, Runx2, OCN);                                                                 7 and 14 days
  ALP activity;                                                                 4, 7 and 14 days                                                                                                                                                                                                                         
  ARS                                                                           7, 14 and 21 days                                                                                                                                                                                                                        
  hDPSCs                                                                        In vitro                                  GNP-CPC                                   Xia et al. \[[@B25-materials-12-01015]\]            RT-PCR (ALP, COL1α, Runx2);                                                                      7 and 14 days
  ALP activity;                                                                 4, 7 and 14 days                                                                                                                                                                                                                         
  ARS                                                                           4, 7, 14 and 21 days                                                                                                                                                                                                                     
  hDPCSs                                                                        In vitro, Animal                          HA-TCP                                    Kyung-Jung et al. \[[@B26-materials-12-01015]\]     In vitro: RT-PCR (ALP, BSP, OPN, DMP-1, DSPP);                                                   10 days
  In vivo: RT-PCR (BSP, OPN, ONT, OCN)                                          8 weeks                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro, Animal                          PCL-BCP                                   Wongsupa et al. \[[@B27-materials-12-01015]\]       RT-PCR (Runx2, ALP, OCN, DSPP);                                                                  7, 14 and 21 days
  Micro-CT;                                                                     2, 4 and 8 weeks                                                                                                                                                                                                                         
  Histomorphometric analysis                                                    2, 4 and 8 weeks                                                                                                                                                                                                                         
  hDPSCs                                                                        In vitro                                  Zn0, Zn1, Zn2, Zn3                        Huang et al. \[[@B28-materials-12-01015]\]          Western blot (DSPP, DMP-1);                                                                      7 and 14 days
  RT-PCR (Runx2, OCN, BSP, BMP-2, MEPE, ON);                                    7 and 14 days                                                                                                                                                                                                                            
  ALP activity;                                                                 1, 4, 7 and 10 days                                                                                                                                                                                                                      
  ARS                                                                           3, 4 and 5 weeks                                                                                                                                                                                                                         
  DPSCs                                                                         Animal                                    HA-TCP                                    Atalayin et al. \[[@B29-materials-12-01015]\]       RT-PCR (DSPP, DMP-1, MMP20, PHEX)                                                                6 and 12 weeks
  hDPSCs                                                                        In vitro                                  SC                                        Theocharidou et al. \[[@B30-materials-12-01015]\]   RT-PCR (DSPP, BMP-2, Runx2, OSX);                                                                7 and 14 days
  ALP activity;                                                                 3, 7 and 14 days                                                                                                                                                                                                                         
  Mineralization analysis using SEM                                             28 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  Quick-Set2, PR-MTA                        Niu et al. \[[@B31-materials-12-01015]\]            RT-PCR (Runx2, OSX, ALP, BSP, OCN, DMP-1, DSPP);                                                 1, 2 and 3 weeks
  Western blot (DMP-1, DSPP, OCN);                                              1, 2 and 3 weeks                                                                                                                                                                                                                         
  ALP activity;                                                                 1, 2 and 3 weeks                                                                                                                                                                                                                         
  ARS;                                                                          1, 2 and 3 weeks                                                                                                                                                                                                                         
  ATR-FTIR;                                                                     1, 2 and 3 weeks                                                                                                                                                                                                                         
  TEM                                                                           1, 2 and 3 weeks                                                                                                                                                                                                                         
  hDPSCs                                                                        In vitro                                  CPC-BGN                                   Lee SI et al. \[[@B32-materials-12-01015]\]         RT-PCR (DMP-1, DSPP, ALP, OPN, OCN, VEGF, (FGF)-2, (VEGFR)-2, VEGFR-1, (PECAM)-1, VE-cadherin;   7 and 14 days
  ALP activity;                                                                 7 and 14 days                                                                                                                                                                                                                            
  ARS                                                                           N/S                                                                                                                                                                                                                                      
  hDPSCs                                                                        In vitro, ex vivo                         SC                                        Bakopoulou et al. \[[@B33-materials-12-01015]\]     RT-PCR (DSPP, BMP-2, Runx2, OSX, ALP, BGLAP);                                                    7 and 14 days
  ALP activity;                                                                 3, 7 and 14 days                                                                                                                                                                                                                         
  hDPSCs                                                                        In vitro                                  BD, TheraCal, MTA                         Bortoluzzi et al. \[[@B34-materials-12-01015]\]     RT-PCR (ALP, OCN, BSP, Runx2, DSPP, DMP-1);                                                      7 days
  ALP activity;                                                                 14 days                                                                                                                                                                                                                                  
  ARS                                                                           14 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  MTA+UW/PG                                 Natu et al. \[[@B35-materials-12-01015]\]           RT-PCR (ALP, OCN, Runx2, DSPP, MEPE);                                                            7 and 14 days
  ARS                                                                           7 and 14 days                                                                                                                                                                                                                            
  hDPSCs                                                                        In vitro                                  BD, PR-MTA                                Widbiller et al. \[[@B36-materials-12-01015]\]      RT-PCR (COL1α, ALP, DSPP, Runx2);                                                                7, 14 and 21 days
  ALP activity                                                                  3, 7 and 14 days                                                                                                                                                                                                                         
  hDPSCs                                                                        In vitro, Animal                          iRoot BP Plus, PR-MTA                     Zhu et al. \[[@B37-materials-12-01015]\]            SEM;                                                                                             1, 3 and 7 days
  ATR-FTIR;                                                                     1, 3 and 7 days                                                                                                                                                                                                                          
  microCT;                                                                      \-                                                                                                                                                                                                                                       
  Histologic analysis;                                                          \-                                                                                                                                                                                                                                       
  Double immunofluorescence                                                     \-                                                                                                                                                                                                                                       
  hDPSCs                                                                        In vitro                                  BD                                        Luo et al. \[[@B38-materials-12-01015]\]            RT-PCR (OCN, DSPP, DMP1, BSP);                                                                   14 days
  ALP activity;                                                                 1, 3, 7, 10 and 14 days                                                                                                                                                                                                                  
  ARS                                                                           14 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  PR-MTA, CEM                               Asgary et al. \[[@B39-materials-12-01015]\]         RT-PCR (FGF4, BMP2, BMP4, TGF-β1, ALP, COL1, DSPP, DMP1);                                        1, 3, 7 and 14 days
  ELISA (FGF4, BMP2, BMP4, TGF-β1);                                             1, 3, 7 and 14 days                                                                                                                                                                                                                      
  ARS                                                                           14 days                                                                                                                                                                                                                                  
  iDPSCs                                                                        In vitro                                  MTA                                       Wang et al. \[[@B40-materials-12-01015]\]           RT-PCR (ALP, Runx2, OSC, OCN, DSPP);                                                             3 and 7 days
  ALP activity;                                                                 3 and 5 days                                                                                                                                                                                                                             
  ARS                                                                           14 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  CaP granules                              Nam et al. \[[@B41-materials-12-01015]\]            RT-PCR (DSPP, DMP1, COL1, OCN);                                                                  7, 14 and 21 days
  ALP activity;                                                                 7, 14 and 21 days                                                                                                                                                                                                                        
  ARS;                                                                          28 days                                                                                                                                                                                                                                  
  Western blot                                                                  21 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro, ex vivo                         PLGA/HA, PLGA/CDHA, PLGA/TCP              Zheng et al. \[[@B42-materials-12-01015]\]          ALP activity;                                                                                    N/S
  Von Kossa staining and Gene Tool analysis                                     4 and 5 weeks                                                                                                                                                                                                                            
  hDPSCs                                                                        In vitro                                  MTA                                       Zhao et al. \[[@B43-materials-12-01015]\]           RT-PCR (ALP, DSPP, COL1, OCN, BSP)                                                               6, 12, 24 and 48 h
  hDPSCs                                                                        In vitro                                  PR-MTA                                    Paranjpe et al. \[[@B44-materials-12-01015]\]       RT-PCR (Runx2, OCN, ALP, DSP)                                                                    1, 4 and 7 days
  hDPSCs                                                                        In vitro                                  DA0, DA0.5, DA1                           Tu et al. \[[@B45-materials-12-01015]\]             TRACP & ALP assay kit (Takahara, Shiga, Japan);                                                  3 and 7 days
  OC and DSP enzyme-linked immunosorbent assay kits (ThermoFisher Scientific)   7 and 14 days                                                                                                                                                                                                                            
  hDPSCs                                                                        In vitro                                  PR-MTA, MTA-CaCl~2~, MTA-Na~2~HPO~4~      Kulan et al. \[[@B46-materials-12-01015]\]          RT-PCR (DSPP, COL1);                                                                             14 and 21 days
  ALP activity;                                                                 7 and 14 days                                                                                                                                                                                                                            
  Von Kossa staining                                                            21 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  CSC                                       Xu et al. \[[@B47-materials-12-01015]\]             ALP activity                                                                                     10 days
  hDPSCs                                                                        In vitro                                  iRoot FS, BD at 0.2 and 2 mg/mL           Sun et al. \[[@B48-materials-12-01015]\]            RT-PCR (COL1, OCN);                                                                              1, 7 and 14 days
  ALP activity;                                                                 7 and 14 days                                                                                                                                                                                                                            
  ARS                                                                           21 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  TheraCal, PR-MTA                          Lee BN et al. \[[@B49-materials-12-01015]\]         RT-PCR (DSPP, DMP1);                                                                             1 and 3 days
  ALP activity;                                                                 7 days                                                                                                                                                                                                                                   
  ARS                                                                           14 days                                                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro, Animal                          BD, MTA                                   Daltoé et al. \[[@B50-materials-12-01015]\]         RT-PCR (SPP1, IBSP, DSPP, ALPL, DMP1, Runx2);                                                    24 and 48 h
  Immunohistochemical assays for OPN y ALP;                                     120 days                                                                                                                                                                                                                                 
  Indirect immunofluorescence for Runx2;                                        120 days                                                                                                                                                                                                                                 
  hDPSCs                                                                        In vitro                                  CaSi-αTCP, CaSi-DCPD                      Gandolfi et al. \[[@B51-materials-12-01015]\]       RT-PCR (ALP, OCN)                                                                                24 h
  hDPSCs                                                                        In vitro                                  MTAP, MTAF                                Mestieri et al. \[[@B52-materials-12-01015]\]       ALP activity                                                                                     1 and 3 days
  hDPSCs                                                                        In vitro                                  BCP at a ratio of 20/80, 50/50 y 80/20    AbdulQader et al. \[[@B53-materials-12-01015]\]     RT-PCR (COL1A1, BSP, DMP1, DSPP);                                                                14, 21 and 28 days
  ALP activity;                                                                 0--3, 3--6, 6--9, 9--12 and 12--15 days                                                                                                                                                                                                  
  hDPSCs                                                                        In vitro                                  CSP                                       Zhang et al. \[[@B54-materials-12-01015]\]          RT-PCR (DMP1, DSPP, Runx2, OPN);                                                                 3 and 10 days
  ALP activity                                                                  3 and 10 days                                                                                                                                                                                                                            
  hDPSCs                                                                        In vitro                                  CPC-N, CPC-M                              Lee SY et al. \[[@B55-materials-12-01015]\]         RT-PCR (DMP1, DSPP, OCN, OPM, BSP);                                                              7 and 14 days
  ALP activity                                                                  7 and 14 days                                                                                                                                                                                                                            
  hDPSCs                                                                        In vitro                                  iRoot BP, MTA diluted at 1:1, 1:2 o 1:5   Öncel Torun et al. \[[@B56-materials-12-01015]\]    RT-PCR (BMP, ON, BSP, OPN, DSPP, COL1A1, HO-1)                                                   24 and 72 h
  hDPSCs                                                                        In vitro                                  Ca~3~SiO~5~                               Peng et al. \[[@B57-materials-12-01015]\]           RT-PCR (ALP, DSPP, DMP1, COL1, OC)                                                               4, 7 and 10 days
  ALP activity;                                                                 4, 7 and 10 days                                                                                                                                                                                                                         
  ARS                                                                           30 days                                                                                                                                                                                                                                  

\* Genes or markers studied in RT-PCR appear inside parentheses.

materials-12-01015-t002_Table 2

###### 

List of commercially available bioceramic materials studied.

  Material                              Abbreviation   Manufacturer                                        Times Studied
  ------------------------------------- -------------- --------------------------------------------------- ---------------
  Mineral Trioxide Aggregate            MTA            Angelus Dental Solutions, Londrina, PR, Brazil      3
  Nano-hydroxiapatite                   Nano-HA        Sigma-Aldrich, UK                                   1
  Biodentine (tricalcium silicate)      BD             Septodont, Saint Maurdes-Fosses, France             7
  Nex-Cem MTA                           Nex MTA        GC, Tokyo, Japan                                    1
  Hydroxiapatite-Tricalcium Phosphate   HA-TCP         OSSTEM Implant Co., Ltd., New Zealand               1
  Zimmer, Warsaw, IN, USA               1                                                                  
  N/S                                   1                                                                  
  ProRoot Mineral Trioxide Aggregate    PR-MTA         Dentsply Tulsa Dental Specialties, Tulsa, OK, USA   10
  Quick-Set2                            \-             Primus Consulting, Bradenton, FL, USA               1
  TheraCal LC                           TheraCal       Bisco Inc., Schaumburg, IL, USA                     2
  iRoot BP Plus                         \-             Innovative Bioceramix, Vancouver, BC, Canada        1
  Calcium-enriched mixture              CEM            BioniqueDent, Tehran, Iran                          1
  Hydroxyapatite                        HA             N/S                                                 1
  iRoot Fast Set root repair material   FS             Innovative Bioceramix, Vancouver, BC, Canada        1
  MTA Plus                              MTAP           Avalon Biomed Inc., Bradenton, FL, USA              1
  MTA Fillapex                          MTAF           Angelus S/A, Londrina, PR, Brazil                   1
  FillCanal                             FC             Technew, Rio de Janeiro, RJ, Brazil                 1
  iRoot BP                              iRoot BP       Innovative Bioceramix, Vancouver, BC, Canada        1

N/S: not specified.

materials-12-01015-t003_Table 3

###### 

List of experimental/novel bioceramic materials studied.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Material                                                           Abbreviation                                                     Composition                                                                                                                   Times Studied
  ------------------------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------
  Calcium-silicate cement containing phosphopullulan                 Exp. PPL                                                         60% portland cement, 20% bismuth oxide, 5% calcium sulfate dehydrate, PPL (5%), other (10%)                                   1

  Gelatin-hydroxyapatite-tricalcium phosphate scaffold               Gelatin-HA-TCP                                                   Three types of powdered gelatin, HA and TCP at a ratio of 10:1:1                                                              1

  Poly-ɛ-caprolactane--biphasic calcium phosphate                    PCL-BCP                                                          80% poly-ɛ-caprolactane, 20% biphasic calcium phosphate                                                                       1

  Zinc Bioglass                                                      Zn0                                                              38.5% SiO~2~, 26.2% Na~2~O, 29.0% CaO, 6.3% P~2~O~5~, 0% ZnO                                                                  1

  Zn1                                                                37.0% SiO~2~, 26.5% Na~2~O, 29.2% CaO, 6.3% P~2~O~5~, 1.0% ZnO   1                                                                                                                             

  Zn2                                                                35.7% SiO~2~, 26.7% Na~2~O, 29.4% CaO, 6.2% P~2~O~5~, 2.0% ZnO   1                                                                                                                             

  Zn3                                                                34.3% SiO~2~, 27.0% Na~2~O, 29.6% CaO, 6.1% P~2~O~5~, 3.0% ZnO   1                                                                                                                             

  Mg-based, Zn-doped bioceramic scaffolds                            SC                                                               60% SiO~2~; 7.5% MgO; 30% CaO; 2.5% ZnO                                                                                       2

  Calcium phosphate porous granules                                  CaP granules                                                     N/S                                                                                                                           1

  Gelatin-hydroxyapatite-tricalcium phosphate                        Gelatin-HA-TCP                                                   A mixture of 3 types of powdered gelatin, HA and TCP at a ratio of 10:1:1 was added to ultrapure water to form the scaffold   1

  Calcium silicate                                                   CaSi                                                             Dicalcium silicate, tricalcium silicate, tricalcium aluminate, calcium sulfate                                                1

  Calcium silicate-alpha tricalcium phosphate                        CaSi-αTCP                                                        Ca~3~(PO~4~)~2~                                                                                                               1

  Calcium silicate-dicalcium phosphate dihydrate                     CaSi-DCPD                                                        CaHPO~4~·2H~2~O                                                                                                               1

  Hydroxyapatite-β-tricalcium phosphate                              BCP                                                              Ca~5~(PO~4~)~3~(OH)/ Ca~3~(PO~4~)~2~ at ratios of 20/80, 50/50 and 80/20                                                      1

  Silicate based Ca7Si2P2O16 bioceramic extract                      CSP                                                              Ca7Si2P2O16 diluted at a 200, 100, 50 and 25 mg/mL                                                                            1

  Calcium phosphate cements in the form of nano and microparticles   CPC-N,\                                                          α-TCP                                                                                                                         1
                                                                     CPC-M                                                                                                                                                                                          

  Tricalcium silicate                                                Ca~3~SiO~5~                                                      Ca~3~SiO~5~                                                                                                                   1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

materials-12-01015-t004_Table 4

###### 

List of bioceramic materials and additives studied.

  Material                                  Bioceramic Material Composition                                                      Additive                               Additive Composition                                                Abbreviation      Times Studied
  ----------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------------------------------- ----------------- ---------------
  Calcium phosphate cement                  Tetracalcium phosphate Ca~4~(PO~4~)~2~O + dicalcium phosphate anhydrous (CaHPO~4~)   Iron oxide nanoparticles               Hematite, αFe~2~O~3~                                                αIONP-CPC         1
  Maghemite, βFe~2~O~3~                     βIONP-CPC                                                                                                                                                                                                         
  Calcium phosphate cement                  Tetracalcium phosphate Ca~4~(PO~4~)~2~O + dicalcium phosphate anhydrous (CaHPO~4~)   Gold nanoparticles                     Gold (III) chloride trihydrate, sodium citrate tribasic dihydrate   GNP-CPC           1
  Calcium phosphate                         α-tricalcium phosphate (Ca~3~(PO~4~)~2~)                                             Bioactive glass nanoparticles          85% SiO~2~, 15% CaO                                                 CPC-BGN           1
  Hydroxyapatite                            Ca~5~(PO~4~)~3~(OH)                                                                  Poly(lactide-co-glycolide)             \-                                                                  PLGA/HA           1
  Hydroxiapatite-Calcium carbonate          CaCO~3~ + Ca~5~(PO~4~)~3~(OH)                                                        Poly(lactide-co-glycolide)             \-                                                                  PLGA/CDHA         1
  Tricalcium phosphate                      Ca~3~(PO~4~)~2~                                                                      Poly(lactide-co-glycolide)             \-                                                                  PLGA/TCP          1
  Mg-based, Zn-doped bioceramic scaffolds   60% SiO~2~; 7.5% MgO; 30% CaO; 2.5% ZnO                                              Low level laser irradiation            \-                                                                  SC + LLLI         1
  Premixed C~3~S/CaCl~2~ paste              C~3~S/CaCl~2~                                                                        Polyethylene glycol                    \-                                                                  CSC               1
  ProRoot MTA                               \-                                                                                   Propylene glycol and ultrapure water   \-                                                                  MTA + UW/PG       1
  ProRoot MTA                               \-                                                                                   Polydopamine                           0 mg/mL polydopamine                                                DA0               1
  0.5 mg/mL polydopamine                    DA0.5                                                                                1                                                                                                                            
  1 mg/mL polydopamine                      DA1                                                                                  1                                                                                                                            
  ProRoot MTA                               \-                                                                                   Calcium chloride                       CaCl~2~                                                             MTA-CaCl~2~       1
  ProRoot MTA                               \-                                                                                   Sodium phosphate dibasic               Na~2~HPO~4~                                                         MTA-Na~2~HPO~4~   1

materials-12-01015-t005_Table 5

###### 

Results of the assessment of in vitro studies by the use of the modified CONSORT checklist \[[@B19-materials-12-01015]\]. Cells marked with an asterisk "\*" represent study fulfilment for the given quality assessment parameter. Cells left blank represent non-fulfilment.

  Studies                                             Modified CONSORT Checklist of Items for Reporting In Vitro Studies of Dental Materials                                                        
  --------------------------------------------------- ---------------------------------------------------------------------------------------- ---- ---- ---- ---- -- -- -- -- -- ---- -- ---- ---- --
  Hanafy et al. \[[@B21-materials-12-01015]\]         \*                                                                                       \*        \*   \*                  \*           \*   
  Pedano et al. \[[@B22-materials-12-01015]\]         \*                                                                                       \*   \*   \*   \*                  \*      \*        
  Gu et al. \[[@B23-materials-12-01015]\]             \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Xia et al. \[[@B24-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Xia et al. \[[@B25-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Kyung-Jung et al. \[[@B26-materials-12-01015]\]     \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Wongsupa et al. \[[@B27-materials-12-01015]\]       \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Huang et al. \[[@B28-materials-12-01015]\]          \*                                                                                       \*        \*   \*                  \*                
  Theocharidou et al. \[[@B30-materials-12-01015]\]   \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Niu et al. \[[@B31-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Lee SI et al. \[[@B32-materials-12-01015]\]         \*                                                                                       \*        \*   \*                  \*           \*   
  Bakopoulou et al. \[[@B33-materials-12-01015]\]     \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Bortoluzzi et al. \[[@B34-materials-12-01015]\]     \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Natu et al. \[[@B35-materials-12-01015]\]           \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Widbiller et al. \[[@B36-materials-12-01015]\]      \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Zhu et al. \[[@B37-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Luo et al. \[[@B38-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Asgary et al. \[[@B39-materials-12-01015]\]         \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Wang et al. \[[@B40-materials-12-01015]\]           \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Nam et al. \[[@B41-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Zheng et al. \[[@B42-materials-12-01015]\]          \*                                                                                       \*        \*   \*                  \*      \*   \*   
  Zhao et al. \[[@B43-materials-12-01015]\]           \*                                                                                       \*        \*   \*                  \*           \*   
  Paranjpe et al. \[[@B44-materials-12-01015]\]       \*                                                                                       \*   \*   \*   \*                  \*      \*        
  Tu et al. \[[@B45-materials-12-01015]\]             \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Kulan et al. \[[@B46-materials-12-01015]\]          \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Xu et al. \[[@B47-materials-12-01015]\]             \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Sun et al. \[[@B48-materials-12-01015]\]            \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Lee BN et al. \[[@B49-materials-12-01015]\]         \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Daltoé et al. \[[@B50-materials-12-01015]\]         \*                                                                                       \*   \*   \*   \*                  \*      \*        
  Gandolfi et al. \[[@B51-materials-12-01015]\]       \*                                                                                       \*   \*   \*   \*                  \*      \*        
  Mestieri et al. \[[@B52-materials-12-01015]\]       \*                                                                                       \*   \*   \*   \*                  \*           \*   
  AbdulQader et al. \[[@B53-materials-12-01015]\]     \*                                                                                       \*   \*   \*   \*                  \*      \*   \*   
  Zhang et al. \[[@B54-materials-12-01015]\]          \*                                                                                       \*   \*   \*   \*                  \*           \*   
  Lee SY et al. \[[@B55-materials-12-01015]\]         \*                                                                                       \*        \*   \*                  \*      \*   \*   
  Öncel Torun et al. \[[@B56-materials-12-01015]\]    \*                                                                                       \*   \*   \*   \*                  \*                
  Peng et al. \[[@B57-materials-12-01015]\]           \*                                                                                       \*   \*   \*   \*                  \*           \*   

materials-12-01015-t006_Table 6

###### 

Results of the assessment of animal studies by the use of the ARRIVE guidelines \[[@B20-materials-12-01015]\].

  Studies                                           ARRIVE Checklist of Items for Reporting In Vivo Experiments (Animal Research)                                                                                         
  ------------------------------------------------- ------------------------------------------------------------------------------- ---- -- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- -- ---- ---- ----
  Kyung-Jung et al. \[[@B26-materials-12-01015]\]   \*                                                                              \*      \*   \*   \*   \*   \*        \*   \*   \*   \*        \*   \*      \*   \*   \*
  Wongsupa et al. \[[@B27-materials-12-01015]\]     \*                                                                              \*      \*   \*   \*   \*   \*   \*   \*   \*   \*   \*   \*   \*   \*      \*   \*   \*
  Atalayin et al. \[[@B29-materials-12-01015]\]                                                                                     \*      \*   \*   \*   \*   \*        \*   \*   \*   \*        \*   \*      \*   \*   \*
  Zhu et al. \[[@B37-materials-12-01015]\]          \*                                                                              \*      \*   \*        \*   \*        \*   \*   \*   \*        \*   \*      \*   \*   \*
  Daltoé et al. \[[@B50-materials-12-01015]\]                                                                                       \*      \*   \*             \*        \*   \*   \*   \*             \*      \*   \*   \*

materials-12-01015-t007_Table 7

###### 

Summary of the results of included studies showing significant differences between various bioceramic materials or different concentrations of the same bioceramic material for osteogenic, odontogenic and/or angiogenic gene expression.

  Author                                             Bioceramics Used                          Significant Results               Gene              Duration             Significance Level
  -------------------------------------------------- ----------------------------------------- --------------------------------- ----------------- -------------------- --------------------
  Pedano et al. \[[@B22-materials-12-01015]\]        Exp. PPL, BD, Nex-MTA                     Exp. PPL, Biodentine \> Nex MTA   DSPP              10 days              *p* \< 0.05
  OCN                                                14 days                                   *p* \< 0.05                                                              
  Biodentine \> Nex MTA                              DSPP                                      14 days                           *p* \< 0.05                            
  Xia et al. \[[@B24-materials-12-01015]\]           αIONP-CPC, βIONP-CPC                      γION-CPC \> αION-CPC              COL1α             14 days              *p* \< 0.05
  Hanafy et al. \[[@B21-materials-12-01015]\]        MTA, Nano-HA                              Nano-HA \> MTA                    OPN, Runx2, OCN   21 days              *p* \< 0.05
  Niu et al. \[[@B31-materials-12-01015]\]           Quick-Set2, PR-MTA                        Quick-Set2 \> PR-MTA              Runx2             1 and 2 weeks        *p* \< 0.001
  OSX                                                2 and 3 weeks                             *p* \< 0.001                                                             
  ALP                                                3 weeks                                   *p* \< 0.001                                                             
  BSP                                                3 weeks                                   *p* \< 0.001                                                             
  PR-MTA \> Quick-Set2                               ALP                                       1 week                            *p* \< 0.001                           
  OCN                                                1, 2 and 3 weeks                          *p* \< 0.001                                                             
  DMP-1                                              1, 2 and 3 weeks                          *p* \< 0.001                                                             
  DSPP                                               2 and 3 weeks                             *p* \< 0.001                                                             
  Sun et al. \[[@B48-materials-12-01015]\]           iRoot FS, BD at 0.2 and 2 mg/mL           FS0.2 \> BD0.2 \> BD2 \> FS2      COL1              7 days               *p* \< 0.05
  FS0.2 \> FS2 \> BD2, BD0.2                         OCN                                       7 days                            *p* \< 0.05                            
  FS0.2 \> BD0.2, BD2 \> FS2                         COL1                                      14 days                           *p* \< 0.05                            
  FS0.2, FS2 \> BD0.2, BD2                           OCN                                       14 days                           *p* \< 0.05                            
  AbdulQader et al. \[[@B53-materials-12-01015]\]    BCP at a ratio of 20/80, 50/50 y 80/20    BCP20 \> BCP50-80                 DMP-1, DSPP       14, 21 and 28 days   *p* \< 0.05
  BSP                                                21 and 28 days                            *p* \< 0.05                                                              
  BCP50 \> BCP80                                     BSP                                       28 days                           *p* \< 0.05                            
  Öncel Torun et al. \[[@B56-materials-12-01015]\]   iRoot BP, MTA diluted at 1:1, 1:2 o 1:5   1:1MTA \> 1:1iRoot BP             OPN, DSPP         72 h                 *p* \< 0.05
  HO1, BMP2, BSP                                     24 and 72 h                               *p* \< 0.05                                                              
  1:1iRoot BP \> 1:1 MTA                             DSPP                                      24 h                              *p* \< 0.05                            
  ON, COL1A1                                         24 and 72 h                               *p* \< 0.05                                                              
  1:2MTA \> 1:2iRoot BP                              BMP2, ON, BSP                             72 h                              *p* \< 0.05                            
  HO1                                                24 and 72 h                               *p* \< 0.05                                                              
  1:2iRoot BP \> 1:2 MTA                             OPN                                       24 h                              *p* \< 0.05                            
  DSPP, COL1A1                                       72 h                                      *p* \< 0.05                                                              
  1:5MTA \> 1:5iRoot BP                              HO1, OPN, ON                              72 h                              *p* \< 0.05                            
  BMP2                                               24 and 72 h                               *p* \< 0.05                                                              

materials-12-01015-t008_Table 8

###### 

Summary of the results of included studies showing significant differences between a bioceramic material with an additive and the bioceramic material itself for osteogenic, odontogenic and/or angiogenic gene expression.

  Author                                              Bioceramics Used                       Significant Results                                        Gene                             Duration         Significance Level
  --------------------------------------------------- -------------------------------------- ---------------------------------------------------------- -------------------------------- ---------------- --------------------
  Xia et al. \[[@B24-materials-12-01015]\]            αIONP-CPC, βIONP-CPC                   γION-CPC, αION-CPC \> CPC                                  COL1α                            7 days           *p* \< 0.01
  ALP, Runx2                                          7 and 14 days                          *p* \< 0.01                                                                                                  
  OCN                                                 14 days                                *p* \< 0.01                                                                                                  
  Xia et al. \[[@B25-materials-12-01015]\]            GNP-CPC                                GNP-CPC \> CPC                                             COL1α, ALP, Runx2                7 and 14 days    *p* \< 0.01
  OCN                                                 14 days                                *p* \< 0.01                                                                                                  
  Theocharidou et al. \[[@B30-materials-12-01015]\]   SC                                     SC + low level laser treatment \> SC                       DSPP, BMP-2, OSX, Runx2          7 and 14 days    *p* \< 0.05
  Lee SI et al. \[[@B32-materials-12-01015]\]         CPC-BGN                                CPC-BGN10% \> CPC-BGN5% \> CPC-BGN2%                       OPN, DSPP, FGF2, VEGF, PECAM-1   7 and 14 days    *p* \< 0.05
  VEGFR1                                              14 days                                *p* \< 0.05                                                                                                  
  CPC-BGN10% \> CPC-BGN2%                             DMP-1, VEGFR2. VE-cadherin             7 and 14 days                                              *p* \< 0.05                                       
  CPC-BGN2, 5, 10% \> CPC-BGN0%                       PECAM-1, DSPP                          7 and 14 days                                              *p* \< 0.05                                       
  ALP, OPN, DMP-1, VEGF, VEGFR1, VE-cadherin          14 days                                *p* \< 0.05                                                                                                  
  CPC-BGN5, 10% \> CPC-BGN0%                          FGF2                                   7 and 14 days                                              *p* \< 0.05                                       
  OPN, VEGF                                           7 days                                 *p* \< 0.05                                                                                                  
  OCN                                                 14 days                                *p* \< 0.05                                                                                                  
  CPC-BGN10% \> CPC-BGN0%                             VEGFR2                                 7 and 14 days                                              *p* \< 0.05                                       
  DMP-1, VE-cadherin                                  7 days                                 *p* \< 0.05                                                                                                  
  Bakopoulou et al. \[[@B33-materials-12-01015]\]     SC                                     hTDM/SC \> SC                                              BMP-2                            7 and 14 days    *p* \< 0.05
  DSPP                                                14 days                                *p* \< 0.05                                                                                                  
  SC \> hTDM                                          Runx2                                  7 days                                                     *p* \< 0.05                                       
  Natu et al. \[[@B35-materials-12-01015]\]           MTA + UW/PG                            MTA + UW/PG (100/0) \> MTA + UW/PG (50/50)                 OCN, DSPP                        14 days          *p* \< 0.05
  Kulan et al. \[[@B46-materials-12-01015]\]          PR-MTA, MTA-CaCl~2~, MTA-Na~2~HPO~4~   MTA-CaCl~2~, MTA-Na~2~HPO~4~ \> PR-MTA + distilled water   COL1, DSPP                       14 and 21 days   *p* \< 0.05

materials-12-01015-t009_Table 9

###### 

Summary of the results of included studies showing significant differences between a bioceramic material and a control for osteogenic, odontogenic and/or angiogenic gene expression.

  Author                                            Bioceramics Used                         Significant Results                                   Gene                         Duration             Significance Level
  ------------------------------------------------- ---------------------------------------- ----------------------------------------------------- ---------------------------- -------------------- --------------------
  Pedano et al. \[[@B22-materials-12-01015]\]       Exp. PPL, BD, Nex-MTA                    Biodentine, Exp. PPL, Nex MTA \< control              ALP                          4 and 14 days        *p* \< 0.05
  DSPP, OCN                                         4 days                                   *p* \< 0.05                                                                                             
  Biodentine \> control                             DSPP, OCN                                10 days                                               *p* \< 0.05                                       
  Biodentine, Ex. PPL \> control                    OCN                                      14 days                                               *p* \< 0.05                                       
  Gu et al. \[[@B23-materials-12-01015]\]           Gelatin-HA-TCP (10:1:1)                  Gel-HA-TCP \> control                                 Runx2                        4 days               *p* \< 0.01
  OSX                                               7 days                                   *p* \< 0.05                                                                                             
  BSP                                               4 days                                   *p* \< 0.05                                                                                             
  Kyung-Jung et al. \[[@B26-materials-12-01015]\]   HA-TCP                                   HA-CPC \> control                                     ALP                          10 days              *p* \< 0.05
  BSP                                               10 days                                  *p* \< 0.001                                                                                            
  Control \> HA-CPC                                 OPN, DMP-1                               10 days                                               *p* \< 0.01                                       
  DSPP                                              10 days                                  *p* \< 0.001                                                                                            
  Huang et al. \[[@B28-materials-12-01015]\]        Zn0, Zn1, Zn2, Zn3                       Zn1, Zn2 \> control                                   Runx2                        7 days               *p* \< 0.01
  Zn0 \> control                                    14 days                                  *p* \< 0.05                                                                                             
  Zn1, Zn2, Zn3 \> control                          14 days                                  *p* \< 0.01                                                                                             
  Zn1 \> control                                    ON                                       7 days                                                *p* \< 0.05                                       
  Zn0, Zn1, Zn2, Zn3 \> control                     14 days                                  *p* \< 0.05                                                                                             
  Zn0 \> control                                    OCN                                      7 days                                                *p* \< 0.01                                       
  Zn3 \> control                                    14 days                                  *p* \< 0.05                                                                                             
  Zn0, Zn1, Zn2, Zn3 \> control                     14 days                                  *p* \< 0.01                                                                                             
  Zn0 \> control                                    MEPE                                     7 days                                                *p* \< 0,05                                       
  Zn1, Zn2, Zn3 \> control                          7 days                                   *p* \< 0.01                                                                                             
  Zn0, Zn1, Zn2, Zn3 \> control                     14 days                                  *p* \< 0.01                                                                                             
  Zn0, Zn1, Zn2, Zn3 \> control                     BSP                                      7 days                                                *p* \< 0.01                                       
  Zn0 \> control                                    14 days                                  *p* \< 0.05                                                                                             
  Zn1, Zn2, Zn3 \> control                          14 days                                  *p* \< 0.01                                                                                             
  Zn1, Zn2, Zn3 \> control                          BMP-2                                    7 days                                                *p* \< 0.05                                       
  Zn0, Zn2, Zn3 \> control                          14 days                                  *p* \< 0.01                                                                                             
  Zn1 \> control                                    14 days                                  *p* \< 0.05                                                                                             
  Bakopoulou et al. \[[@B33-materials-12-01015]\]   SC                                       SC \> control                                         DSPP, BMP-2, BGLAP           7 and 14 days        *p* \< 0.05
  OSX                                               14 days                                  *p* \< 0.05                                                                                             
  Control \> SC                                     ALP                                      7 and 14 days                                         *p* \< 0.05                                       
  Runx2                                             14 days                                  *p* \< 0.05                                                                                             
  Niu et al. \[[@B31-materials-12-01015]\]          Quick-Set2, PR-MTA                       Quick-Set2, PR-MTA \> control                         Runx2                        1 and 2 weeks        *p* \< 0.001
  OSX, DSPP                                         2 and 3 weeks                            *p* \< 0.001                                                                                            
  ALP                                               1 and 3 weeks                            *p* \< 0.001                                                                                            
  BSP                                               3 weeks                                  *p* \< 0.001                                                                                            
  OCN, DMP-1                                        1, 2 and 3 weeks                         *p* \< 0.001                                                                                            
  Bortoluzzi et al. \[[@B34-materials-12-01015]\]   BD, TheraCal LC, MTA                     Biodentine, MTA \> control                            ALP, OCN, BSP, DSPP, DMP-1   7 days               *p* \< 0.0085
  Luo et al. \[[@B38-materials-12-01015]\]          BD                                       Biodentine 0.2 mg/mL, Biodentine 2 mg/mL \> control   OCN, DSPP, DMP1, BSP         14 days              *p* \< 0.05
  Wang et al. \[[@B40-materials-12-01015]\]         MTA                                      MTA \> control                                        OCN                          3 days               P \< 0.05
  Runx2, OSX, DSPP                                  3 and 7 days                             *p* \< 0.01                                                                                             
  ALP, OCN                                          7 days                                   *p* \< 0.01                                                                                             
  Nam et al. \[[@B41-materials-12-01015]\]          CaP granules                             CaP \> control                                        DSPP, DMP1, OCN              21 days              *p* \< 0.01
  COL1                                              14 days                                  *p* \< 0.05                                                                                             
  CaP \> control                                    COL1, OCN, DSPP                          7 days                                                *p* \< 0.01                                       
  DMP1                                              14 days                                  *p* \< 0.05                                                                                             
  Zhao et al. \[[@B43-materials-12-01015]\]         MTA                                      MTA \> control                                        ALP, DSPP, COL1, BSP         6, 12, 24 and 48 h   *p* \< 0.05
  OCN                                               12, 24 and 48 h                          *p* \< 0.05                                                                                             
  MTA 0.2 mg/mL, MTA 2 mg/mL \> control             ALP, DSPP, COL1, BSP, OCN                48 h                                                  *p* \< 0.05                                       
  Paranjpe et al. \[[@B44-materials-12-01015]\]     MTA                                      MTA \> control                                        OCN, ALP, DSP                7 days               *p* \< 0.05
  Runx2                                             4 days                                   *p* \< 0.05                                                                                             
  Sun et al. \[[@B48-materials-12-01015]\]          iRoot FS, BD at 0.2 and 2 mg/mL          Control \> BD2                                        COL1                         1 and 7 days         *p* \< 0.05
  OCN                                               7 days                                   *p* \< 0.05                                                                                             
  Control \> BD0.2, FS0.2, FS2                      COL1                                     7 days                                                *p* \< 0.05                                       
  FS0.2 \> control                                  OCN                                      7 days                                                *p* \< 0.05                                       
  COL1                                              14 days                                  *p* \< 0.05                                                                                             
  Lee BN et al. \[[@B49-materials-12-01015]\]       TheraCal, PR-MTA                         PR-MTA \> control                                     DSPP                         1 and 3 days         *p* \< 0.05
  DMP                                               3 days                                   *p* \< 0.05                                                                                             
  Theracal \> control                               DSPP, DMP                                3 days                                                *p* \< 0.05                                       
  Daltoé et al. \[[@B50-materials-12-01015]\]       BD, MTA                                  Biodentine, MTA \> control                            SPP1, ALPL, Runx2            48 h                 *p* \< 0.05
  Gandolfi et al. \[[@B51-materials-12-01015]\]     CaSi-αTCP, CaSi-DCPD                     CaSi-αTCP \> control                                  ALP, OCN                     24 h                 *p* \< 0.05
  Zhang et al. \[[@B54-materials-12-01015]\]        CSP diluted at 200, 100, 50 y 25 mg/mL   CSP25, CSP50, CSP100, CSP200 \> control               DSPP, DMP1                   10 days              *p* \< 0.05
  Runx2                                             3 and 10 days                            *p* \< 0.05                                                                                             
  CSP50, CSP100, CSP200 \> control                  DSPP, DMP1, OPN                          3 days                                                *p* \< 0.05                                       
  CSP100, CSP200 \> control                         OPN                                      10 days                                               *p* \< 0.05                                       
  Peng et al. \[[@B57-materials-12-01015]\]         Ca~3~SiO~5~                              Ca~3~SiO~5~ \> control                                ALP, DSPP                    4, 7 and 10 days     *p* \< 0.05
  OC, DMP1                                          7 and 10 days                            *p* \< 0.05                                                                                             

materials-12-01015-t010_Table 10

###### 

Summary of the results of included studies showing significant differences between a bioceramic material and a non-bioceramic material for osteogenic, odontogenic and/or angiogenic gene expression.

  Author                                            Bioceramics Used   Other Material Used             Bioactivity Analysis                  Significant Results        Gene            Duration           Significance Level
  ------------------------------------------------- ------------------ ------------------------------- ------------------------------------- -------------------------- --------------- ------------------ --------------------
  Kyung-Jung et al. \[[@B26-materials-12-01015]\]   HA-TCP             Demineralized dentin matrix     RT-PCR (ALP, BSP, OPN, DMP-1, DSPP)   DDM \> HA-CPC              ALP, BSP, OPN   10 days            *p* \< 0.05
  DMP-1                                             10 days            *p* \< 0.01                                                                                                                         
  DSPP                                              10 days            *p* \< 0.001                                                                                                                        
  Peng et al. \[[@B57-materials-12-01015]\]         Ca~3~SiO~5~        Calcium Hydroxide (Ca(OH)~2~)   RT-PCR (ALP, COL1, OC, DSPP, DMP1)    Ca~3~SiO~5~ \> Ca(OH)~2~   ALP, DSPP       4, 7 and 10 days   *p* \< 0.05
  Ca(OH)~2~ \> Ca~3~SiO~5~                          OC, DMP1           7 and 10 days                   *p* \< 0.05                                                                                         
  DMP1                                              4 days             *p* \< 0.05                                                                                                                         

materials-12-01015-t011_Table 11

###### 

Summary of the results of included studies showing significant differences between various bioceramic materials or different concentrations of the same bioceramic material for ARS staining.

  Author                                        Bioceramics Used       Significant Results    Duration         Significance Level
  --------------------------------------------- ---------------------- ---------------------- ---------------- --------------------
  Xia et al. \[[@B24-materials-12-01015]\]      αIONP-CPC, βIONP-CPC   γION-CPC \> αION-CPC   14 and 21 days   *p* \< 0.05
  Niu et al. \[[@B31-materials-12-01015]\]      Quick-Set2, PR-MTA     PR-MTA \> Quick-Set2   2 and 3 weeks    *p* \< 0.001
  Lee BN et al. \[[@B49-materials-12-01015]\]   TheraCal, PR-MTA       PR-MTA \> Theracal     14 days          *p* \< 0.05

materials-12-01015-t012_Table 12

###### 

Summary of the results of included studies showing significant differences between a bioceramic material with an additive and the bioceramic material itself for ARS staining.

  Author                                     Bioceramics Used       Significant Results         Duration         Significance Level
  ------------------------------------------ ---------------------- --------------------------- ---------------- --------------------
  Xia et al. \[[@B24-materials-12-01015]\]   αIONP-CPC, βIONP-CPC   γION-CPC, αION-CPC \> CPC   7 and 14 days    *p* \< 0.05
  Xia et al. \[[@B25-materials-12-01015]\]   GNP-CPC                GNP-CPC \> CPC              14 and 21 days   *p* \< 0.01

materials-12-01015-t013_Table 13

###### 

Summary of the results of included studies showing significant differences between a bioceramic material and a control for ARS staining.

  Author                                            Bioceramics Used                  Significant Results                                   Duration           Significance Level
  ------------------------------------------------- --------------------------------- ----------------------------------------------------- ------------------ --------------------
  Gu et al. \[[@B23-materials-12-01015]\]           Gelatin-HA-TCP (10:1:1)           Gel-HA-TCP \> control                                 18 days            *p* \< 0.01
  21 days                                           *p* \< 0.05                                                                                                
  Huang et al. \[[@B28-materials-12-01015]\]        Zn0, Zn1, Zn2, Zn3                Zn0, Zn1, Zn2, Zn3 \> control                         3 weeks            *p* \< 0.05
  Zn1, Zn2, Zn3 \> control                          4 and 5 weeks                     *p* \< 0.05                                                              
  Niu et al. \[[@B31-materials-12-01015]\]          Quick-Set2, PR-MTA                PR-MTA, Quick-Set2 \> control                         1, 2 and 3 weeks   *p* \< 0.001
  Bortoluzzi et al. \[[@B34-materials-12-01015]\]   BD, TheraCal, MTA                 Biodentine, TheraCal, MTA \> control                  7 and 14 weeks     *p* \< 0.05
  Luo et al. \[[@B38-materials-12-01015]\]          BD                                Biodentine 0.2 mg/mL, Biodentine 2 mg/mL \> control   14 days            *p* \< 0.05
  Wang et al. \[[@B40-materials-12-01015]\]         MTA                               0.2 mg/mL MTA \> control                              14 days            *p* \< 0.01
  Nam et al. \[[@B41-materials-12-01015]\]          CaP granules                      CaP \> control                                        28 days            *p* \< 0.01
  Sun et al. \[[@B48-materials-12-01015]\]          iRoot FS, BD at 0.2 and 2 mg/mL   FS0.2 \> control                                      21 days            *p* \< 0.05
  Lee BN et al. \[[@B49-materials-12-01015]\]       TheraCal, PR-MTA                  PR-MTA, Theracal \> control                           14 days            *p* \< 0.05
  Peng et al. \[[@B57-materials-12-01015]\]         Ca~3~SiO~5~                       Ca~3~SiO~5~ \> control                                30 days            *p* \< 0.05

materials-12-01015-t014_Table 14

###### 

Summary of the results of included studies showing significant differences between various bioceramic materials or different concentrations of the same bioceramic material for ALP activity.

  Author                                            Bioceramics Used                         Significant Results             Duration                            Significance Level
  ------------------------------------------------- ---------------------------------------- ------------------------------- ----------------------------------- --------------------
  Xia et al. \[[@B24-materials-12-01015]\]          αIONP-CPC, βIONP-CPC                     γION-CPC \> αION-CPC            14 days                             *p* \< 0.05
  Niu et al. \[[@B31-materials-12-01015]\]          Quick-Set2, PR-MTA                       PR-MTA \> Quick-Set2            2 and 3 weeks                       *p* \< 0.001
  Zheng et al. \[[@B42-materials-12-01015]\]        PLGA/HA, PLGA/CDHA, PLGA/TCP             PLGA/TCP \> PLGA/HA, PLG/CDHA   N/S                                 *p* \< 0.05
  Sun et al. \[[@B48-materials-12-01015]\]          iRoot FS, BD at 0.2 and 2 mg/mL          FS0.2, FS2, BD0.2 \> BD2        7 days                              *p* \< 0.05
  FS0.2 \> BD0.2 \> BD2, FS2                        14 days                                  *p* \< 0.05                                                         
  Mestieri et al. \[[@B52-materials-12-01015]\]     MTAP, MTAF                               MTAP \> MTAF                    1 y 3 days                          *p* \< 0.05
  AbdulQader et al. \[[@B53-materials-12-01015]\]   BCP at a ratio of 20/80, 50/50 y 80/20   BCP20 \> BCP50, BCP20           3--6, 6--9, 9--12 and 12--15 days   *p* \< 0.05
  BCP50 \> BCP80                                    9--12 and 12--15 days                    *p* \< 0.05                                                         
  Lee SY et al. \[[@B55-materials-12-01015]\]       CPC-N, CPC-M                             CPC-N \> CPC-M                  7 and 14 days                       *p* \< 0.05

materials-12-01015-t015_Table 15

###### 

Summary of the results of included studies showing significant differences between a bioceramic material with an additive and the bioceramic material itself for ALP activity.

  Author                                              Bioceramics Used                       Significant Results                                        Duration        Significance Level
  --------------------------------------------------- -------------------------------------- ---------------------------------------------------------- --------------- --------------------
  Xia et al. \[[@B24-materials-12-01015]\]            αIONP-CPC,βIONP-CPC                    γION-CPC, αION-CPC \> CPC                                  7 days          *p* \< 0.05
  14 days                                             *p* \< 0.01                                                                                                       
  Xia et al. \[[@B25-materials-12-01015]\]            GNP-CPC                                GNP-CPC \> CPC                                             7 and 14 days   *p* \< 0.01
  Theocharidou et al. \[[@B30-materials-12-01015]\]   SC                                     SC + LLLI \> SC                                            7 days          *p* \< 0.05
  SC \> SC + LLLI                                     14 days                                *p* \< 0.05                                                                
  Lee SI et al. \[[@B32-materials-12-01015]\]         CPC-BGN                                CPC-BGN2, 5, 10% \> CPC-BGN0%                              7 and 14 days   *p* \< 0.05
  Kulan et al. \[[@B46-materials-12-01015]\]          PR-MTA, MTA-CaCl~2~, MTA-Na~2~HPO~4~   MTA-CaCl~2~, MTA-Na~2~HPO~4~ \> PR-MTA + distilled water   N/S             *p* \< 0.01

materials-12-01015-t016_Table 16

###### 

Summary of the results of included studies showing significant differences between a bioceramic material and a control for ALP activity.

  Author                                            Bioceramics Used                         Significant Results                                   Duration            Significance Level
  ------------------------------------------------- ---------------------------------------- ----------------------------------------------------- ------------------- --------------------
  Gu et al. \[[@B23-materials-12-01015]\]           Gelatin-HA-TCP (10:1:1)                  Gel-HA-TCP \> control                                 4 days              *p* \< 0.05
  7 and 12 days                                     *p* \< 0.01                                                                                                        
  Huang et al. \[[@B28-materials-12-01015]\]        Zn0, Zn1, Zn2, Zn3                       Zn3 \> control                                        1 day               *p* \< 0.05
  Zn0, Zn1, Zn2, Zn3 \> control                     7 and 10 days                            *p* \< 0.05                                                               
  Niu et al. \[[@B31-materials-12-01015]\]          Quick-Set2, PR-MTA                       PR-MTA, Quick-Set2 \> control                         1, 2 and 3 weeks    *p* \< 0.001
  Bakopoulou et al. \[[@B33-materials-12-01015]\]   SC                                       SC \> control                                         3, 7 and 14 days    *p* \< 0.05
  Bortoluzzi et al. \[[@B34-materials-12-01015]\]   BD, TheraCal, MTA                        Biodentine, MTA, TheraCal \> control                  14 days             *p* \< 0.05
  Widbiller et al. \[[@B36-materials-12-01015]\]    BD, PR-MTA                               Control \> MTA                                        3, 7 and 14 days    *p* \< 0.05
  Luo et al. \[[@B38-materials-12-01015]\]          BD                                       Biodentine 0.2 mg/mL, Biodentine 2 mg/mL \> control   7, 10 and 14 days   *p* \< 0.05
  Biodentine 0.2 mg/mL \> control                   3 days                                   *p* \< 0.05                                                               
  Wang et al. \[[@B40-materials-12-01015]\]         MTA                                      0.02 mg/mL MTA \> control                             3 days              *p* \< 0.05
  0.2 mg/mL MTA \> control                          3 and 5 days                             *p* \< 0.01                                                               
  2 mg/mL MTA \> control                            5 days                                   *p* \< 0.01                                                               
  Control \> 20 mg/mL MTA                           3 and 5 days                             *p* \< 0.01                                                               
  Nam et al. \[[@B41-materials-12-01015]\]          CaP granules                             CaP \> control                                        14 and 21 days      *p* \< 0.01
  Xu et al. \[[@B47-materials-12-01015]\]           CSC                                      CSC \> control                                        10 days             *p* \< 0.05
  Sun et al. \[[@B48-materials-12-01015]\]          iRoot FS, BD at 0.2 and 2 mg/mL          BD0.2, BD2, FS0.2, FS2 \> control                     7 and 14 days       *p* \< 0.05
  Lee BN et al. \[[@B49-materials-12-01015]\]       TheraCal, PR-MTA                         MTA \> control                                        7 days              *p* \< 0.05
  Mestieri et al. \[[@B52-materials-12-01015]\]     MTAP, MTAF                               Control \> MTAP, MTAF                                 1 and 3 days        *p* \< 0.05
  Zhang et al. \[[@B54-materials-12-01015]\]        CSP diluted at 200, 100, 50 y 25 mg/mL   CSP50, CSP100, CSP200 \> control                      3 and 10 days       *p* \< 0.05
  Peng et al. \[[@B57-materials-12-01015]\]         Ca~3~SiO~5~                              Ca~3~SiO~5~ \> control                                10 days             *p* \< 0.05

materials-12-01015-t017_Table 17

###### 

Summary of the results of included studies showing significant differences for another bioactivity-related analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                                        Bioceramics Used               Bioactivity Analysis                                           Significant Results             Gene              Duration            Significance Level
  ----------------------------------------------------------------------------- ------------------------------ -------------------------------------------------------------- ------------------------------- ----------------- ------------------- --------------------
  Huang et al. \[[@B28-materials-12-01015]\]                                    Zn0, Zn1, Zn2, Zn3             Western Blot                                                   Zn0, Zn1, Zn2, Zn3 \> control   DSPP              7 days              *p* \< 0.05

  Control \> Zn0, Zn1, Zn2, Zn3                                                 DSPP                           14 days                                                        *p* \< 0.05                                                           

  Zn2, Zn3 \> control                                                           DMP-1                          7 days                                                         *p* \< 0.05                                                           

  Control \> Zn0, Zn1, Zn2, Zn3                                                 DSPP                           14 days                                                        *p* \< 0.05                                                           

  Niu et al. \[[@B31-materials-12-01015]\]                                      Quick-Set2, PR-MTA             Western Blot                                                   PR-MTA \> Quick-Set2            DMP-1 DSPP, OCN   1, 2 and 3 weeks\   *p* \< 0.001\
                                                                                                                                                                                                                                2 and 3 weeks       *p* \< 0.001

  PR-MTA, Quick-Set2 \> control                                                 DMP-1\                         1, 2 and 3 weeks\                                              *p* \< 0.001\                                                         
                                                                                DSPP                           2 and 3 weeks                                                  *p* \< 0.001                                                          

  PR-MTA \> control                                                             OCN                            1, 2 and 3 weeks                                               *p* \< 0.001                                                          

  ATR-FTIR                                                                      PR-MTA \> Quick-Set2           \-                                                             2 and 3 weeks                   *p* \< 0.001                          

  PR-MTA, Quick-Set2 \> control                                                 \-                             1, 2 and 3 weeks                                               *p* \< 0.001                                                          

  Asgary et al. \[[@B39-materials-12-01015]\]                                   MTA, CEM                       ELISA                                                          MTA \> CEM                      TFG-β1            N/S                 *p* \< 0.05

  CEM \> MTA                                                                    FGF4                           N/S                                                            *p* \< 0.05                                                           

  Zheng et al. \[[@B42-materials-12-01015]\]                                    PLGA/HA, PLGA/CDHA, PLGA/TCP   Gene Tool (level of grey in mineralization nodules analysis)   PLGA/TCP \> PLGA/HA, PLG/CDHA   \-                4 weeks             *p* \< 0.05

  PLGA/TCP \> PLGA/HA                                                           \-                             5 weeks                                                        *p* \< 0.05                                                           

  Tu et al. \[[@B45-materials-12-01015]\]                                       DA0, DA0.5, DA1                TRACP & ALP assay kit (Takahara, Shiga, Japan)                 DA0.5, DA1 \> DA0               ALP               7 days              *p* \< 0.05

  DA1 \> DA0                                                                    ALP                            3 days                                                         *p* \< 0.05                                                           

  DA0.5, DA1 \> DA0                                                             OCN                            7 and 14 days                                                  *p* \< 0.05                                                           

  OC and DSP enzyme-linked immunosorbent assay kits (ThermoFisher Scientific)   DA1 \> DA0                     DSP                                                            7 days                          *p* \< 0.05                           

  DA0.5, DA1 \> DA0                                                             DSP                            14 days                                                        *p* \< 0.05                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

materials-12-01015-t018_Table 18

###### 

Summary of the significant results of included studies categorized as animal studies.

  Author                                            Bioceramics Used              Non-Bioceramic Material Used                                        In Vivo Assay Description                                                                                                                      Bioactivity Analysis                                    Results                       Gene   Duration        Significance Level
  ------------------------------------------------- ----------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ----------------------------- ------ --------------- --------------------
  Kyung-Jung et al. \[[@B26-materials-12-01015]\]   HA-TCP                        Demineralized dentin matrix                                         Ectopic bone fomation in athymic rats with HA-(HA-TCP or DDM) and HDPSCs implanted subcutaneously.                                             RT-PCR                                                  HA-TCP \> DDM                 BSP    8 weeks         *p* \< 0.001
  Wongsupa et al. \[[@B27-materials-12-01015]\]     PCL-BCP                       \-                                                                  Bone formation in 1mm diameter calvarial defects in the parietal bone in 5--6-month-old male New Zealand white rabbits.                        Micro-CT                                                PCL-BCP + hDPSCs \> PCL-BCP   \-     4 and 8 weeks   *p* \< 0.01
  Hysto-morphometric anaysis                        PCL-BCP + hDPSCs \> PCL-BCP   \-                                                                  2, 4 and 8 weeks                                                                                                                               *p* \< 0.01                                                                                                  
  Atalayin et al. \[[@B29-materials-12-01015]\]     HA-TCP                        L-lactide/DL-lactide copolymer (PLDL), DL-lactide copolymer (PDL)   Odontogenic differentiation of hDPSCs in rats implanted with HA-CPC and hDPSCs subcutaneously.                                                 RT-PCR (DSPP, DMP-1, MMP20, PHEX)                       PDL \> PLDL, HA/TCP           DSPP   12 weeks        *p* \< 0.05
  PLDL \> PDL, HA-TCP                               DMP1                          6 weeks                                                             *p* \< 0.05                                                                                                                                                                                                                                                 
  HA-TCP \> PLDL, PDL                               12 weeks                      *p* \< 0.05                                                                                                                                                                                                                                                                                                                     
  PLDL, HA/TCP \> PDL                               MMP20                         6 weeks                                                             *p* \< 0.05                                                                                                                                                                                                                                                 
  PDL \> PLDL, HA/TCP                               12 weeks                      *p* \< 0.05                                                                                                                                                                                                                                                                                                                     
  HA-TCP \> PLDL, PDL                               PHEX                                                                                              *p* \< 0.05                                                                                                                                                                                                                                                 
  PLDL \> PDL, HA-TCP                                                             *p* \< 0.05                                                                                                                                                                                                                                                                                                                     
  Daltoé et al. \[[@B50-materials-12-01015]\]       BD, MTA                       \-                                                                  87 specimens of 2nd and 3rd upper premolars and 2nd, 3rd, and 4th lower premolars from 4 dogs (Beagles), evaluated 120 days after pulpotomy.   Staining for OPN and ALP in mineralized tissue bridge   MTA \> BD                     OPN    120 days        *p* \< 0.001
  BD \> MTA                                         ALP                           120 days                                                            *p* \< 0.001                                                                                                                                                                                                                                                
  Staining for OPN and ALP in pulp tissue           BD \> MTA                     OPN                                                                 120 days                                                                                                                                       *p* \< 0.001                                                                                                 
